Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Karyopharm Therapeutics, Inc
This study aims to assess effectiveness, safety and affect on quality of life for two drug regimes using a combination of targeted therapy drugs and corticosteroids to treat patients that have recurrent Multiple Myeloma and have previously undergone 1-3 treatments for Multiple Myeloma. Patients eligible to participate in this trial will receive either 5 doses of Selinexor, 4 doses of Bortezomib and 10 doses of Dexamthasone for each 35 day cycle, or 4 doses of Bortezomib and 8 doses of Dexamthasone for the first 8 x 21 day cycles.